News and Trends 3 Oct 2022
Oxford BioTherapeutics enters into antibody agreement with Genmab
Oxford BioTherapeutics (OBT) says Genmab has licensed a novel antibody related to one of OBT's IO programs. The target was discovered using Oxford BioTherapeutics' OGAP drug discovery platform, which incorporates…